Fenfluramine low dose - Zogenix

Drug Profile

Fenfluramine low dose - Zogenix

Alternative Names: Brabafen; Fintepla; Low-dose fenfluramine; ZX-008

Latest Information Update: 12 May 2017

Price : $50

At a glance

  • Originator Brabant Pharma
  • Developer Brabant Pharma; Katholieke Universiteit Leuven; University of Antwerp; Zogenix
  • Class Amphetamines; Anorectics; Antiepileptic drugs; Small molecules
  • Mechanism of Action Serotonin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lennox-Gastaut syndrome; Dravet syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase III Dravet syndrome
  • Phase II Lennox-Gastaut syndrome
  • Preclinical Epilepsy

Most Recent Events

  • 04 May 2017 Zogenix plans a phase III trial in Lennox-Gastaut syndrome
  • 04 May 2017 Zogenix receives two additional patents for method of use of ZX 008 in Dravet syndrome in USA
  • 27 Apr 2017 Zogenix completes enrolment in the phase III Study 1 trial for Dravet syndrome (Adjunctive treatment, In adolescents, In children) in Australia, Canada, Europe and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top